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Abstract 
Review on t(11;21)(p14;q22) RUNX1/KIAA1549L 
BL, with data on clinics, and the genes implicated. 
Identity 
G-banded partial karyotype of a patient with a 
t(11;21)(p14;q22). Arrows indicate derivative 
chromosomes.Clinics and pathology 
Disease 
Acute myeloid leukemia (AML), AML-M1 by FAB 
subtype 
Phenotype/cell stem origin 
CD13, CD19, CD33, CD34, and HLA-DR were 
positive. 
Epidemiology 
This is a rare chromosomal rearrangement. A case 
of MDS with t(11;21)(p14;q22) involving the 
RUNX1 locus with RUNX1 gene amplification 
(Moosavi et al., 2009) and a case of AML-M4 with 
t(11;21)(p13;q22) (Arber et al., 2002) were 
previously reported. This case is only one AML 
patient characterized at molecular level to date (Abe 
et al., 2012). 
Clinics 
A 78-year-old man suffering from bleeding 
tendency and fatigue with dyspnea for one month 
was diagnosed as AML. 
Leukemic cells had large nuclei and little cytoplasm without 
azure granules. 
Cytology 
Blast morphology showed minimal differentiation 
implicating AML M1. Leukemia cells were weakly 
positive for myeloperoxidase and negative for 
esterase. 
Pathology 
Bone marrow examination at diagnosis showed 
hypocellular marrow with 57% leukemic blasts. 
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Treatment 
The patient received two courses of remission 
induction chemotherapy with daunorubicin and 
cytarabine, however, a complete remission was not 
achieved. The leukemia cells were slow-growing in 
the early period after diagnosis, so that he received 
11 cycles of low dose cytarabine after induction 
failure and lived for 2 years. He was died from 
progression of leukemia possible with intracranial 
hemorrhage. 
Genes involved and 
proteins 
KIAA1549L 
Location 
11p13-14 
Note 
KIAA1549L is also known as C11ORF41 or 
C11ORF69. The function of KIAA1549L is not 
known.  
Northern blot analysis of several human tissues 
detected two transcripts of 11 and 7.9 kb in brain 
(Gawin et al., 1999). KIAA1549L indicates a 
KIAA1549-like ortholog. KIAA1549 is known as a 
fusion partner of BRAF in pilocytic astrocytomas 
(Jones et al., 2008). 
DNA/RNA 
The KIAA1549L gene contains 20 exons spanning 
132 kb of genomic DNA. Four transcripts are 
known. Transcription orientation: telomere to 
centromere. 
Protein 
The predicted KIAA1549L proteins contain 1849 
amino acids, 199 kDa. 
RUNX1 
Location 
21q22 
DNA/RNA 
Transcription orientation: telomere to centromere. 
Protein 
The predicted RUNX1 proteins contain 250, 453 
and 480 amino acids designated as RUNX1a, 
RUNX1b and RUNX1c, respectively.  
All 3 proteins contain the 128-amino acid Runt 
domain, but RUNX1a does not contain a 
transcriptional activation domain of C-terminal 
region. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5' RUNX1-KIAA1549L 3'. 
Transcript 
Two types of in-frame RUNX1-KIAA1549L fusion 
transcripts were detected. One was a fusion 
between exon 5 of RUNX1 and exon 13 of 
KIAA1549L (Type 1) and the other was between 
exon 6 of RUNX1 and exon 13 of KIAA1549L 
(Type 2). A reciprocal KIAA1549L-RUNX1 fusion 
was not detected. Both fusion transcripts include 
the region encoding Runt homology domain of 
RUNX1. 
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